Chronic kidney disease : a complex network of leukocyte dysfunction and inflammation by Mansouri, Ladan
From  
DEPARTMENT OF MEDICINE SOLNA 
Karolinska Institutet, Stockholm, Sweden 
CHRONIC KIDNEY DISEASE: 
A COMPLEX NETWORK OF LEUKOCYTE 
DYSFUNCTION AND INFLAMMATION 
Ladan Mansouri 
یروصنم ندلا 
 
Stockholm 2016 
 
  
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print AB 2016, Stockholm Sweden. 
© Ladan Mansouri, 2016 
ISBN 978-91-7676-401-5 
Department of Medicine Solna 
 
Chronic kidney disease: A complex network of  
leukocyte dysfunction and inflammation 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
 
The public defense at Karolinska Institutet will be held at Rolf Luft auditorium, CMM 
Ground floor (L1:00), Karolinska University Hospital Solna 
 
Friday, November 11
th
 2016, 09:00 
By 
Ladan Mansouri, MD. 
Principal Supervisor: 
Professor Joachim Lundahl        
Karolinska Institutet 
Department of Medicine Solna 
Unit of Immunology and Allergy 
 
Co-supervisor(s): 
Docent Anna Nopp 
Karolinska Institutet 
Department of Medicine Solna 
Unit of Immunology and Allergy 
 
Professor Stefan Jacobson 
Karolinska Institutet 
Danderyd Hospital 
Department of Clinical Sciences 
 
Opponent: 
Professor Mårten Segelmark 
Linköping University 
Department of Medical and Health Sciences 
 
 
Examination Board: 
Docent Guro Gafvelin 
Karolinska Institutet 
Department of Clinical Neuroscience 
 
Professor Börje Haraldsson 
University of Gothenburg  
Department of Medicine 
Division of Molecular and Clinical Medicine 
 
Docent Ann-Charlotte Wikström 
Karolinska Institutet 
Department of Medicine Solna 
Unit of Immunology and Allergy 
 
 
Stockholm 2016
  
 
To my loved ones, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   “Excellence is never an accident.  
                     It is always the result of high intention, sincere effort, and intelligent execution. 
                     It represents the wise choice of many alternatives  
                     - Choice, not chance, determines your destiny” 
 
                                                                                                       ― Aristotle   
 
  
 
  
ABSTRACT 
Chronic kidney disease (CKD) is a common medical condition with a prevalence of up to 
13% worldwide. The insidious loss of renal function develops over time to reach end stage 
renal disease (ESRD) when the kidneys are unable to remove toxins and interventions such as 
dialysis or kidney transplantation are mandatory. These patients are at increased risk of 
morbidity and mortality, essentially due to cardiovascular diseases and infections, which arise 
from alterations in both the innate and adaptive immune responses. This thesis focuses on the 
functional aberrations in leukocytes, inflammation and outcomes of medical interventions in 
CKD patients. In paper I, we investigated the impact of blood-membrane interaction on 
circulating basophils and neutrophils in hemodialysis patients (stage 5D) using dialyzers with 
two different pore sizes; high-flux and low-flux. Passage through the low-flux dialyzer 
induced a significant up-regulation of the activation marker CD63 on basophils, while this 
was not the case in high-flux dialysis. No significant differences were observed in the 
expression of neutrophil activation markers (CD11b, the active epitope of CD11b, and 
CD88), either comparing the two dialyzers, or compared to healthy controls. In paper II, we 
analyzed the proliferation of lymphocytes and production of pro-inflammatory molecules 
following in vitro stimulation of whole blood from pre-dialysis (CKD stage 3-4), 
hemodialysis patients (stage 5D), and healthy individuals. We found a similar absolute 
number of lymphoblasts, and CD4+ and CD8+ subpopulation in response to stimulation 
when comparing the three groups. However, levels of selected cytokines were lower in the 
staphylococcus enterotoxin A (SEA)-, influenza A vaccine (IAV)-, and pokeweed mitogen 
(PWM)-stimulated supernatants from hemodialysis patients compared to those in pre-dialysis 
and healthy controls. In paper III, we aimed to investigate whether the decreased in vitro 
cytokine production results from dysfunction of T cells per se. We analyzed the T 
lymphocyte profile in CKD patients (stage 5D) following stimulation of isolated CD4+ cells 
with an antigen-independent stimulator (SEA). The proportion of CD4+CD25+FOXP3+ 
(Treg) and CD4+GATA3+ (Th2) cells was significantly lower in patients. Levels of 
Interleukin (IL)-4 were significantly lower in supernatants from patients, while Interferon 
(IFN)-γ levels were higher. IL-10 levels did not differ, comparing patients to healthy 
individuals. In paper IV, we performed a clinical trial for 12 weeks with the vitamin D 
receptor activator (VDRA)-paricalcitol and placebo in patients with moderate CKD (stage 3-
4). We observed that selected pro-inflammatory cytokines decreased following VDRA 
treatment but not in the placebo group. Micro RNAs: 432-5p, 495-3p, and 576-5p were also 
significantly down regulated in the active treated group compared to the placebo group. 
In conclusion, we demonstrate that chronic renal impairment and hemodialysis leads to a high 
inflammatory state and alteration in the function of innate and adaptive immune cells. 
Moreover, we show that treatment with active vitamin D-paricalcitol has a positive impact on 
dampening inflammatory molecules and miRs involved in atherosclerosis and inflammation. 
Altogether, these findings provide us with a better understanding of potential factors 
orchestrating the higher prevalence of cardiovascular diseases and infections, as well as the 
progression of CKD.  
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1 INTRODUCTION 
1.1 CHRONIC KIDNEY DISEASE (CKD) 
1.1.1 Definition and staging 
The kidneys are vital organs, which remove wastes and extra fluids, keep electrolytes in 
balance, regulate blood pressure (by renin), manage the production of red blood cells (by 
erythropoietin), and bone metabolism (by active vitamin D). Chronic kidney disease (CKD) 
comprises heterogeneous disorders, which affect the performance or structure of the kidney. 
The presence or absence of kidney damage (albuminuria, kidney biopsy findings, or imaging 
abnormalities) and declined level of kidney function (glomerular filtration rate, GFR <60 
mL/min/1.73 m
2
) for more than three months, define CKD, irrespective of diagnosis (Levey 
and Coresh 2012). 
A simplified classification of CKD into different stages based on GFR is as follows; 
Stage 1: GFR >90 (Kidney damage with normal GFR) 
Stage 2: GFR 60-89 (Mild) 
Stage 3: GFR 30-59 (Moderate) 
Stage 4: GFR 15-29 (Severe) 
Stage 5: GFR <15 (Kidney failure) 
There is a normal age-related decline of GFR in adults, which follows global glomerular 
sclerosis and cortical atrophy, but the consequences of this phenomenon have not been 
thoroughly studied in elderly, age ≥65 years (Denic, Glassock et al. 2016). 
1.1.2 Epidemiology 
In recent years, guidelines have stated that CKD is a common disorder with various degrees 
of severity. Currently CKD ranks 19
th
 as mortality cause worldwide, presenting an 82% 
increase since 1990 (Stanifer, Muiru et al. 2016). The prevalence of CKD stage 1-5 in adults 
has been reported between 3-17% with a substantial variation across Europe (Bruck, Stel et 
al. 2016). According to recent estimations in the United States, the disease prevalence in 
adults will increase significantly in the next decade (Hoerger, Simpson et al. 2015). The 
prevalence of CKD is not well characterized in low- and middle-income countries, however a 
higher exposure to occupational and environmental toxins, infections, and medical conditions 
such as: diabetes mellitus (DM), hypertension, obesity, poly cystic kidney disease, acute 
kidney injuries, and malignancies ensures an enormous increase of CKD prevalence in these 
countries (Stanifer, Muiru et al. 2016). 
Altogether, these reports indicate that CKD is a growing medical condition, which requires 
attention, effective prevention, early detection and management. Early stages of the disease 
are usually asymptomatic and possibly reversible, but when kidney failure is established, only 
controlling the comorbidities, dialysis or transplantation is applicable.    
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1.1.3 CKD-related complications 
The enormous burden of the disease is not limited to decreased removal of uremic toxins 
from the body, it also imposes an increased risk of complications associated to the eGFR <60 
mL/min/1.73 m
2
 or albumin/creatinine ratio >30 g/mol.  
These complications comprise cardiovascular diseases, hypertension, mineral and bone 
disorders, anemia, progression to ESRD, infections and low response to vaccinations (Levey, 
de Jong et al. 2011). Cardiovascular diseases and infections are the most common causes of 
morbidity and mortality in CKD patients (Thompson, James et al. 2015). 
1.1.4 Detection  
Since serum creatinine testing is included in the basic metabolic panels, detection of CKD 
mostly occurs during routine care. There are more accurate assessments than serum creatinine 
to determine GFR (clearance of inulin, 
51
Cr-EDTA or iohexol). 
1.1.4.1 Estimated Glomerular Filtration Rate 
GFR is estimated by equations using serum creatinine and combination of age, sex, ethnicity 
and body size (estimated GFR; eGFR). The modification of diet in renal disease (MDRD) 
and the chronic kidney disease epidemiology collaboration (CKD-EPI) equations are accurate 
at eGFRs <60 and eGFRs >60, respectively. Generally CKD-EPI is less biased compared to 
the older MDRD equation (Levey, Stevens et al. 2009). 
1.1.4.2 Quantification of albuminuria 
A spot albumin/creatinine ratio in urine is a sensitive measure of kidney damage, and is 
crucial to evaluate prognosis (Inker, Astor et al. 2014). 
1.1.4.3 Imaging or serologic testing 
Imaging is not routinely required, but in the case of urinary tract stones, frequent urinary tract 
infections, or a family history of polycystic kidney disease (PKD), a kidney and bladder 
ultrasound should be performed. A systemic or glomerular disease requires serologic workup. 
1.1.5 Management 
The main goals of CKD management are to delay progressive loss of kidney function and to 
prevent and manage complications. Currently the most commonly applied strategies to 
prevent progression of the disease and associated complications include treatment of 
hypertension and reduction of albuminuria by use of Angiotensin converting enzyme 
inhibitor (ACE-I), and Angiotensin II receptor blockers (ARBs). Furthermore, diabetes 
control, anemia management (Erythropoiesis-stimulating agent; ESA), correction of 
secondary hyperparathyroidism, hypocalcemia, and hyperphosphatemia (supplementation 
with vitamin D, calcimimetics, and phosphate binders), correction of metabolic acidosis and 
lipid-lowering therapy (statins) are important measures in CKD patients with risk of 
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cardiovascular diseases (Uhlig, Berns et al. 2010; National Kidney 2012; Kliger, Foley et al. 
2013; Taler, Agarwal et al. 2013; Sarnak, Bloom et al. 2015). 
1.2 CKD AND THE IMMUNE SYSTEM 
1.2.1 Immune system 
The immune system is a complex network of cells and soluble factors, which contribute to 
protection of host against various microorganisms and diseases. It is not only involved in 
detection and removal of invading factors, but also contributes to the repair of injured tissues. 
The immune system comprises two main sectors: the innate and the adaptive immune 
systems. The innate immunity performs as a ready-to-go defender. Innate immune cells 
recognize conserved microbial components through their pattern recognition receptors 
(PRRs), and mediate blockage or elimination of infections at a fast pace. The main 
components of innate immunity are physical epithelial barriers, leukocytes such as 
neutrophils, monocytes, macrophages, dendritic cells (DCs), natural killer cells (NKCs), mast 
cells, eosinophils, basophils, and circulating plasma proteins such as complements. The 
adaptive immunity is a slower but more specialized and antigen-specific immune defense 
with a memory to mount a stronger response on re-encounter of the same pathogen. T-
lymphocytes and B-lymphocytes are players in the adaptive immunity.  
Although innate and adaptive immunity are classified separately, they interact very closely, 
and antigen-presenting cells (APCs) are the major links. APCs process and present the 
antigenic peptides on major histocompatibility complex (MHC) to the T cells, and activate 
them to further proliferate, release the inflammatory molecules, boost other immune cells, 
promote antibody production, or convey apoptosis. 
1.2.2 Immunity in CKD 
It’s known that loss of renal function is strongly associated with two contrasting features. On 
the one hand there is a high inflammatory state in CKD patients, which is witnessed by high 
level of pro-inflammatory molecules in the plasma; such as Interleukin (IL)-1, IL-6 and 
Tumor necrosis factor (TNF)-α (Honda, Qureshi et al. 2006; Cohen, Phillips et al. 2010), 
oxidative stress (Locatelli, Canaud et al. 2003), and activation of immune cells such as 
monocytes. This ongoing inflammation leads to processes such as atherosclerosis and 
cardiovascular diseases. On the other hand there is an immunodeficiency, which results in a 
higher susceptibility to infections (Sarnak and Jaber 2000), increased risk of virus-associated 
cancers (Stewart, Vajdic et al. 2009) and a low response to vaccinations  (Robinson 2004).  
The immune system aberrations in CKD patients originate mainly from retention of uremic 
toxins and cytokines or medical interventions such as in dialysis (Betjes 2013).  
1.2.3 Uremia 
When CKD is progressing to ESRD (eGFR <15 mL/min/1.73 m
2
), uremia develops. Patients 
may present characteristic signs and symptoms of uremia such as nausea, significant weight 
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loss, neurologic dysfunction, bleeding diathesis, and volume overload, which may require 
renal replacement therapy. However in many cases, advanced CKD may be asymptomatic 
with very few and uncharacteristic signs and symptoms. 
1.2.3.1 Uremic toxins 
Since serum urea and creatinine are inadequate markers of uremic toxicity, various 
classification systems have been developed to further characterize uremia. 
One is based on the physicochemical properties of uremic toxins, and their removal by renal 
replacement therapy, dividing them into small water-soluble molecules (molecular weight 
≤500 Da), middle molecules (>500 Da), and protein-bound molecules (Vanholder, De Smet 
et al. 2003). Another classification divides them, according to their site of origin, into those 
produced by endogenous metabolism or microbial metabolism and toxins ingested from an 
exogenous source (e.g. oxalate and advanced glycation) (Evenepoel, Meijers et al. 2009).  
The vast majority of uremic toxins are either highly protein bound or middle molecular 
weight compounds, which are difficult to remove by conventional dialysis. 
1.2.3.2 Impact of uremic toxins on the immune system 
There is a strong connection between residual renal function and the level of inflammatory 
markers such as IL-6 (Pecoits-Filho, Heimburger et al. 2003). Loss of renal function leads to 
retention of cytokines and uremic toxins, which in turn result in activation of immune cells 
and oxidative stress. Reactive oxygen species (ROS) can interact with the pattern recognition 
receptors on immune cells, activate them and establish a more sustained inflammatory 
response (Bierhaus, Schiekofer et al. 2001). Moreover, this inflammatory state is 
accompanied by an immune system dysfunction, including defective phagocytosis, 
insufficient antigen presentation, and low T cell-dependent response to vaccination 
(Eleftheriadis, Antoniadi et al. 2007). There are different underlying mechanisms behind 
these phenomena, among which are: decreased responsiveness of activated immune cells 
(tachyphylaxis) (Hendrikx, van Gurp et al. 2009), activation-induced apoptosis, variation in 
differentiation status, and the new paradigm of premature immunological aging in CKD 
patients (Meier, Dayer et al. 2002; Majewska, Baj et al. 2003; Betjes and Litjens 2015). 
1.2.4 Renal replacement therapy 
The ultimate aim of renal replacement therapy is to remove accumulated uremic toxins, 
minerals and excessive fluid from the blood, and to preserve residual renal function. 
Replacement therapy is performed by either hemodialysis (HD) (Fig. 1) or peritoneal dialysis 
(PD), and through diffusion and convection processes. However, blood-dialysis membrane 
interactions may lead to a variety of adverse reactions in circulating immune cells and plasma 
proteins as a consequence of bio-incompatibility. 
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1.2.4.1 Hemodialysis and biocompatibility 
Surface material of the applied dialyzer, membrane permeability properties and dialysis fluid 
(dialyzate) are among the main causes of alterations in adhesion molecule expression on 
leukocytes, cytokine production, phagocytic efficiency, apoptosis, ROS production, and 
complement activation (Kazatchkine and Carreno 1988; Rao, Guo et al. 2004; Banche, 
Allizond et al. 2006). Modified dialysis membranes with improved biocompatibility have 
been developed, which preserve the functionality of immune cells (Banche, Allizond et al. 
2006). Moreover, the membrane permeability affects biocompatibility of the dialyzers. 
Efficient removal of larger molecules such as β2-microglobulin and toxins has been observed 
with high-flux membranes (with large pore size and higher ultrafiltration coefficients) rather 
than with low-flux membranes (with smaller pore size and lower ultrafiltration coefficients). 
The long-term clinical consequences in terms of morbidity and mortality are still under 
debate (Cheung, Levin et al. 2003; Locatelli, Martin-Malo et al. 2009).  
    
 
 Figure 1. Schematic view of hemodialysis procedure. 
 
1.3 CKD AND NEUTROPHILS 
1.3.1 Neutrophil biology 
Neutrophilic granulocytes are the most abundant immune cells, and form a frontier in the 
immune defense. During maturation, a variety of proteins are synthesized, sorted into 
different granules, and stored in neutrophils (Borregaard and Cowland 1997; Borregaard 
2010). Plasticity and significant phenotypical changes are observed in neutrophils at different 
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states of maturity. Under normal circumstances, the circulatory neutrophils reside in the 
resting phase and keep the granules intact. However when primed and activated, they are able 
to execute a range of functions. This requires the neutrophils to leave the circulation and 
migrate to the site of inflammation.  
Neutrophils engulf and phagocytize the pathogens, following recognition of pathogen-
associated molecular patterns (PAMPs) by PRRs or opsonization through FcγR or 
complement receptors. They neutralize or degrade the microbes by releasing their granule 
contents: antimicrobial peptides and proteolytic enzymes, as well as generation of ROS. Up 
on stimulation, they can release chromatin DNA, histones and granular proteins, called 
neutrophil extracellular traps (NETs), to control the pathogens extracellularly. By producing 
cytokines and chemokines, they cross talk and activate other immune cells such as monocyte, 
DCs and NKCs, in addition to the autocrine effect. Moreover, in recent years they have been 
proposed as MHC-II holders, which can be involved in antigen presentation and activation of 
T cells (Kambayashi and Laufer 2014).  
1.3.1.1 Neutrophil extravasation: Rolling, adhesion and transmigration 
Neutrophil extravasation comprises a series of events, and a variety of molecules that 
facilitate the cascade. Under inflammatory circumstances, endothelial cells become directly 
or indirectly (by cytokines) activated, upregulate the expression of adhesion molecules such 
as P-selectin and E-selectin, which interact with ligands such as P-selectin glycoprotein 
ligand 1 (PSGL1) and L-selectins on neutrophils. This leads to capturing of circulatory 
neutrophils, and subsequent rolling along the vessel (Yago, Shao et al. 2010). A variety of 
kinases in neutrophils become activated by this interaction, which results in upregulation of 
adhesion molecules of β2 integrin family: lymphocyte function-associated antigen 1 (LFA-1; 
CD11a/CD18) and macrophage-1 antigen (Mac-1; CD11b/CD18). These molecules interact 
with their endothelial ligand, intercellular adhesion molecule-1 (ICAM-1), and induce a firm 
adhesion and crawling (Cinamon, Shinder et al. 2004). Finally, upon arrival to an endothelial 
junction, neutrophils traverse intercellularly, and transmigrate to the site of inflammation 
under influence of chemoattractants. Neutrophils can also migrate transcellularly, directed 
differently by projection of pseudopods into the endothelial cells (Cinamon, Shinder et al. 
2004). While transmigrating, neutrophils interact with the active domains of extracellular 
matrix (ECM) proteins such as sequences arginine-glycine-aspartic acid (RGD), through the 
integrins, which promote integrin-mediated neutrophil adhesion and migration (Gonzalez, 
Gobin et al. 2004). Having reached the site, neutrophils carry out their actions such as 
releasing the granule contents, phagocytosis, NETosis and eliminate the invading factors. 
During these processes, the oxidative burst machinery also becomes activated.  
1.3.1.2 CD11b expression on neutrophils  
CD11b joins CD18 to form the heterodimeric glycoprotein Mac-1, which is expressed on 
neutrophils, monocytes, macrophages and NKC. The relative abundance of the molecule on 
the surface of the cells depends on the cell type and state of activation. There are remarkable 
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intracellular storage pools within granules of circulating neutrophils. Under resting 
conditions, the CD11b/CD18 molecules are randomly distributed on the surface of the cells  
(Fig. 2). When the neutrophil becomes activated, a rapid translocation of granules to the 
surface results in a tremendous increase in the surface expression and aggregation of 
CD11b/CD18 (Arnaout 1990). Moreover conformational changes of the CD11b molecule 
will take place and establish an activation epitope to bind to the ligands such as ICAM and 
RGD sequences of ECM proteins with a high affinity. CD11b/CD18 interactions lead to 
adhesion and trans-endothelial migration, chemotaxis, phagocytosis of opsonized particles, 
and degranulation (Schleiffenbaum, Moser et al. 1989; Le Cabec, Carreno et al. 2002; Feng, 
Zhang et al. 2011).  
 
 
  
Figure 2. Neutrophil activation with stimuli, translocation of CD11b from granules to the surface of 
the cells, and conformational changes in CD11b (CD11b-active epitope). 
 
1.3.1.3 C5aR expression on neutrophils  
The complement system is a part of innate immunity and consists of a variety of serum 
proteins. Following exposure to PAMPs, a cascade of proteolytic activities occurs, which 
leads to cleavage of downstream molecules. C5a is one of the complement fragments with 
different roles, as a conventional anaphylatoxin and a potent neutrophil and macrophage 
chemoattractant (Snyderman, Pike et al. 1975). A high level of C5a is observed in 
inflammatory conditions. C5a interacts with its receptor (C5aR or CD88) on the surface of 
the cells such as neutrophils and induces upregulation of adhesion molecules, release of 
granule enzymes, and oxidative burst (Mollnes, Brekke et al. 2002; Perianayagam, 
Balakrishnan et al. 2002; Kourtzelis, Markiewski et al. 2010). 
1.3.2 Neutrophils in CKD patients 
A wide range of functional aberrations in the circulatory neutrophil has been observed in the 
CKD patients. Neutrophils present a declined phagocytic capacity with increasing levels of 
Stimuli 
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renal impairment (Mahajan, Kalra et al. 2005; Sardenberg, Suassuna et al. 2006), which 
improves with hemodialysis (Vanholder, Ringoir et al. 1991). They have a significantly lower 
antimicrobial killing activity (Anding, Gross et al. 2003). High levels of plasma light chains 
in advanced CKD can inhibit the chemotaxis of neutrophils (Cohen, Haag-Weber et al. 1995). 
A high oxidative burst activity is present in neutrophils from CKD patients, indicating a 
primed state of these cells in the uremic milieu, a systemic oxidative stress, and systemic 
inflammation (Klein, McLeish et al. 1999; Sela, Shurtz-Swirski et al. 2005).  
It has been shown that neutrophils from CKD patients have a preserved capacity in terms of 
transendothelial migration, but their expression of the adhesion molecule CD11b is 
significantly reduced at the site of inflammation (Jacobson, Thylen et al. 2002; Dadfar, 
Lundahl et al. 2004). In the course of hemodialysis, CD11b expression on circulatory 
neutrophils changes, using a variety of dialyzers with different surface materials (Bonomini, 
Sirolli et al. 1999), and permeability properties (Moshfegh, Jacobson et al. 2002). Yet, a more 
biocompatible dialyzer may preserve the transmigration properties (Moshfegh, Jacobson et al. 
2002), and may contribute to a conserved CD11b expression on neutrophils (Olsson, Dadfar 
et al. 2007). 
Dialyzer composition has a significant impact on C5a generation (Zhang, Liu et al. 2011). 
Higher levels of C5a are observed following hemodialysis (Erlenkotter, Endres et al. 2008; 
Itoh, Takeshita et al. 2008; Inoshita, Ohsawa et al. 2012). Excess stimulation of neutrophils 
with C5a can lead to downregulation of C5aR due to cleavage of the receptor (van den Berg, 
Tambourgi et al. 2014), and therefore an impaired complement-dependent phagocytosis and 
impaired neutrophil function. 
Yet, it is noteworthy that there are many contrasting data in terms of neutrophil behavior and 
expression of different molecules and receptors. This could originate in differences between 
studied individuals, the stage of renal disease, present comorbidities, treatment modalities, 
diverse methods and different conditions of the experiments (Hirabayashi, Kobayashi et al. 
1988; Iida, Umezawa et al. 1997; Klein, McLeish et al. 1999; Gastaldello, Husson et al. 2000; 
Pereira, Costa et al. 2010).  
1.4 CKD AND BASOPHILS 
1.4.1 Basophil biology 
Basophils belong to the granulocyte family and constitute less than 1% of circulating 
leukocytes. They are traditionally known for the storage and release of histamine and 
leukotrienes C4 (LTC4), involved in allergic reactions and anaphylaxis by induction of 
vascular reaction, exudation, and leukocyte accumulation, as well as eradicating helminthes. 
The mediators are released following cross-linking of immunoglobulin (Ig) E receptors 
(FcεRI) on basophils, by interaction of receptor-bound IgE with corresponding antigen. 
However, in recent years, we have learned that the role of basophils is not limited to IgE-
mediated reactions. They express a wide range of receptors such as toll-like receptors (TLR)- 
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2 and 4, IL-3R, IL-33R, C5aR, and chemokine receptors. They are also involved in the 
regulation of other immune cells (Rivellese, Suurmond et al. 2014) and release cytokines 
such as IL-4 and IL-13. Furthermore, they have the capacity to induce Th2 immune responses 
and induce the Ig class switching in B lymphocytes (Denzel, Maus et al. 2008; Schneider, 
Thieblemont et al. 2010; Sokol and Medzhitov 2010; Karasuyama, Mukai et al. 2011). They 
are also introduced as antigen-presenting cells for T cells (Sokol, Chu et al. 2009). 
There are low affinity receptors for IgG on basophils, FcγRIIA (activating) and FcγRIIB 
(inhibiting) with which the cell activation deviates from IgE-dependent path (Cassard, 
Jonsson et al. 2012), and promotes vascular permeability, anaphylaxis and inflammation 
through release of platelet-activating factor (PAF). 
1.4.1.1 FcεRI-mediated activation in basophils 
FcεRI is a high-affinity IgE receptor, which plays an important role in activation of basophils. 
Binding of a multivalent antigen (allergen) to several FcεRI-bound IgE molecules results in 
aggregation of receptors (cross-linking), initiation of activation and degranulation. Expression 
of FcεRI is dependent on the level of IgE in the serum. Higher levels of IgE positively 
correlate to a higher density of the receptor on the basophil surface (MacGlashan, Bochner et 
al. 1997). 
1.4.1.2 N Formyl- Methionyl-Leucyl-Phenylalanine (fMLP) response in basophils  
FMLP is a peptide, with both endogenous (mitochondrial proteins from ruptured cells) and 
exogenous source (bacterial proteins). The interaction of fMLP with its G protein-coupled 
receptor Formylpeptide receptor (FPR), and variant FPR-like 1 and 2 (FPRL 1, 2) generates 
signals to induce chemotaxis and release of histamine and leukotrienes from basophils in an 
IgE-independent manner (MacGlashan, Bochner et al. 1997; Miura and MacGlashan 2000; 
de Paulis, Montuori et al. 2004).   
1.4.1.3 Identification and activation marker 
Different surface markers are used for the identification of basophils. CD203c is a 
glycosylated type II transmembrane molecule, which is expressed exclusively on basophils, 
mast cells and their precursor cells. Moreover, expression intensity of the molecules is low on 
resting basophils, but becomes upregulated on activation. Therefore, it can be counted as both 
an identification and activation marker (Buhring, Streble et al. 2004). 
Another marker to identify basophil activation is CD63 (Knol, Mul et al. 1991). CD63 is the 
most important and applicable activation marker in basophils, which co-exists in the same 
granule as histamine. Therefore, presence of CD63 on the surface of basophils correlates to 
basophil degranulation and release of histamine and leukotrienes (MacGlashan 2010). 
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1.4.2 Basophils in CKD patients 
There is no clear picture as to whether basophils are affected by the course of CKD or 
contribute to the development of complications. Hemodialysis patients, with symptoms such 
as pruritus, show high levels of IgE antibodies as well as a higher level of histamine release in 
vitro, regardless of the dialyzer type (Cavaillon, Poignet et al. 1990). Hemodialysis can 
induce inflammatory mediators such as IL-1β, TNFα and anaphylatoxins that may affect 
basophil function in terms of histamine release (Subramanian and Bray 1987). 
During the dialysis procedure, production of bradykinin may be triggered (Verresen, Fink et 
al. 1994), which in turn can activate the basophils in an IgE-independent manner and induce 
anaphylactoid reactions during the session (Ebo, Bosmans et al. 2006). 
Interestingly, a high level of autoreactive IgE has been observed in patients with lupus 
nephritis together with an accumulation of basophils in the spleen and lymph nodes. These 
IgE antibodies may activate the basophils and induce their migration to lymphoid organs 
where they promote Th2 differentiation, and subsequently B-cell potentiation and further 
production of autoantibodies that convey enforcement of the disease (Charles, Hardwick et al. 
2010). 
1.5 CKD AND T LYMPHOCYTES 
1.5.1 T cell biology 
T lymphocytes are the mainstay of cell-mediated adaptive immunity. They carry a unique T-
cell receptor (TCR) with diverse recognition repertoire. When the APCs; dendritic cells, 
macrophages, or B cells, present the antigenic peptides to T cells, an antigen-specific 
activation of naive cells occurs, which leads to the development of effector and memory T-
cells. Effector cells can convey their function by direct destruction of the target (CD8+ T 
cells, or cytotoxic T cells) or by supporting recruitment, activation and maturation of other 
immune cells through secretion of cytokines (CD4+ T cells, or T helper cells). Moreover, T 
cells are involved in the development of tolerance and anti-inflammatory responses.  
1.5.1.1 CD4+ T helper cells 
Being activated, helper T cells differentiate into a variety of subsets, depending on the stimuli 
and the cytokines present in the milieu. These subsets were initially classified based on 
production of distinct signature cytokines. Later, the master regulators (transcription factors) 
were introduced, which not only promote the production of signature cytokines by the cell but 
also dampen the development of opposing lineage in some subsets. When polarized, T cells 
produce cytokines, which further reinforce the polarization toward that subset. 
Traditionally Th1 and Th2 were recognized as the main subsets, but over time other 
phenotypes were introduced such as Th9, Th17, and Th22, and follicular helper T (Tfh) cells 
(Chang, Sehra et al. 2010; Basu, O'Quinn et al. 2012; Liu, Nurieva et al. 2013). Additionally, 
regulatory T cells (Treg) are known as the anti-inflammatory subset (Fig. 3). 
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Th1 cells are responsible for the activation of macrophages and B-cells through production of 
IFN-γ and contribute to the immune defense against intracellular microorganisms. The master 
regulator of Th1 cells, T-box transcription factor (T-bet), promotes the IFN-γ production as 
well as the suppression of Th2 and Th17 differentiation (Afkarian, Sedy et al. 2002; Djuretic, 
Levanon et al. 2007). Th2 cells, recognized by their cytokines IL-4, IL-5, IL-13, and 
transcription factor GATA-Binding Protein 3 (GATA3), are involved in immune reactions 
against extracellular pathogens, humoral immunity and allergic diseases (Zheng and Flavell 
1997). Regulatory T cells are divided into natural thymus-derived subset (nTreg), and 
peripheral-induced Treg cells (iTreg). They play an important role in maintaining the 
immunologic tolerance by production of cytokines such as IL-10, which inhibits the pro-
inflammatory responses, and suppresses allergic reactions together with TGF-β. The master 
regulator of Tregs is forkhead box P3 (FOXP3) (Sakaguchi, Ono et al. 2006; Ouyang, Rutz et 
al. 2011). 
Interestingly, it has been shown that the antigen-experienced T cells are not restricted to 
one terminally differentiated subset, but rather retain some plasticity to acquire new 
characteristics and functions upon antigenic re-encounter. The factors and environmental 
characteristics promoting the plasticity or stability of human T cell subsets still remain to be 
understood (Geginat, Paroni et al. 2014). 
 
             
Figure 3. CD4+ effector T cell subsets; signature transcription factors, and related cytokines. 
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1.5.2 T-cells in CKD patients 
The disturbances in the cell-mediated immunity start in the early stages of renal failure and 
CKD patients with mild disease present a different immune pattern, compared to 
hemodialysis patients. There are two different overviews on what gives rise to these 
aberrations. There is a T cell dysregulation conception, indicating that abnormality in T cell 
function results from disturbances in antigen presentation and co-stimulation by APCs, and 
pro-inflammatory molecules in the milieu (Dinarello 1992; Girndt, Kohler et al. 1993; Kelly 
1994). However, another conception claims that these disturbances originate in T cell 
dysfunction per se. Patients with renal failure exhibit changes in the proliferation and 
phenotype of T cells, and premature aging of the adaptive immune response (Raska, Raskova 
et al. 1983; Daichou, Kurashige et al. 1999; Nitta, Akiba et al. 2002; Alvarez-Lara, Carracedo 
et al. 2004; Costa, Lima et al. 2008; Betjes and Litjens 2015). Yet, there is no common view 
on these aberrations. In terms of proliferation capacity of T cells in response to different 
stimuli, there are mixed findings of being either normal or decreased. In some studies Th1 is 
introduced as the main effector T cell, while others pinpoint alternative phenotypes such as 
Th2 or Th17 (Sester, Sester et al. 2000; Libetta, Rampino et al. 2001; Yokoyama, Nitta et al. 
2001; Zhang, Hua et al. 2010; Ma, Zhang et al. 2015). Variation in the proportion of FOXP3+ 
Tregs in patients has been observed from being normal to declined (Lisowska, Debska-
Slizien et al. 2012). These aberrations have also been connected to the occurrence of 
complications in CKD patients. For instance, it has been shown that generation of oxidized 
LDL (oxLDL) in hemodialysis patients enhances the CD4+CD25+ Treg sensitivity to Fas-
mediated apoptosis and leads to a decreased proportion of these cells. Meanwhile a Th1-
mediated immune response occurs in atherosclerosis when oxLDL is uptaken by APCs in the 
vessels (Meier, Meier et al. 2008). The changes in T cell function can also affect the humoral 
immunity and B cell response, which causes low response to vaccinations (Dumann, Meuer 
et al. 1990). Moreover, the exacerbated immune activation and cytokine network constantly 
provoke the immune cells, and therefore they become too exhausted to respond to an acute 
challenge.  
The current scattered data can again arise from differences in groups of patients, 
interventions, and analysis approaches. 
1.6 GENE TRANSCRIPTION AND EPIGENETIC REGULATION IN CKD 
As mentioned earlier, a defective immune system and a chronic inflammatory state are 
features of chronic renal failure. Retention of uremic toxins and the dialysis procedure are the 
main contributors to the occurrence of complications. Many efforts have been made to 
investigate and demonstrate the biological-cellular alterations, and molecular changes in these 
patients. Analysis of gene transcription and epigenetic regulations can contribute to an 
increased understanding of the biological mechanisms behind these aberrations. 
Genomic techniques allow us to analyze the whole transcriptome of the cell. Following 
analysis of gene expression data, a number of significant genes are identified and enrolled to 
  13 
different molecular pathways and functional categories. Comparison of gene expression 
profiles between patients and healthy individuals can provide us with valuable findings. Yet, 
it is difficult to choose the right candidates with clinical relevance for further validation 
(Perco, Pleban et al. 2006). 
The genetic basis of many medical conditions has been studied, however gene 
polymorphisms are not the only explanation for different traits and complications. There are 
other factors that can regulate the gene expression and the eventual phenotype. These factors 
are known as epigenetic changes. Epigenetics comprises changes in gene expression without 
alteration in the primary genes and is mainly divided into DNA methylation, histone 
modification and RNA interference such as microRNAs (miRs). These modifications or 
interferences lead to a change in the level of target protein, and an altered phenotype (Egger, 
Liang et al. 2004). 
1.6.1 Transcriptome analysis in CKD 
The underlying biological mechanisms involved in dysfunction of the innate and adaptive 
immune system in CKD are of interest. There are reports on the transcriptomic profile of 
peripheral mononuclear immune cells in CKD patients and differences between treatment 
groups (Zaza, Pontrelli et al. 2008; Zaza, Granata et al. 2013). Polymorphism of different 
cytokine genes such as TGF-β and IL-6 has been connected to progression of kidney disease 
and complications (Girndt, Kaul et al. 2002; Rao, Guo et al. 2004; Liu, Berthier-Schaad et al. 
2006). Genes involved in oxidative metabolism such as Superoxide dismutase-2 (SOD2) are 
shown to be expressed differently in activated neutrophils from CKD patients (Olsson, 
Jacobson et al. 2011).  
1.6.2 Role of microRNAs in CKD 
MicroRNAs are small non-coding RNAs, which interfere with the translation of mRNA by 
silencing or degrading them (Bartel 2009). They contribute to the regulation of a variety of 
cell functions such as proliferation, differentiation and apoptosis, and they are shown to be 
involved in the regulation of immune function (Chen, Li et al. 2004; Backdahl, Bushell et al. 
2009). 
Several miRs are presented to play a role in normal kidney function (Backdahl, Bushell et al. 
2009), as well as in disease process (Badal and Danesh 2015). The dysregulation of selected 
miRs can lead to proteinuria, renal failure (Zhdanova, Srivastava et al. 2011), ESRD (Szeto, 
Ching-Ha et al. 2012), and cardiovascular complications (Ji, Cheng et al. 2007). Moreover, 
miR inhibition has been shown to have therapeutic effects in different groups (Macconi, 
Tomasoni et al. 2012; Putta, Lanting et al. 2012; Zhong, Chung et al. 2013).  
The circulatory miRs are considered as non-invasive biomarkers for certain human diseases. 
In acute kidney failure, it has been reported that miRs are not removed during the 
hemodialysis procedure, perhaps due to transportation by larger proteins or microvesicles. 
Hence, miRs may be good candidates as biomarkers (Martino, Lorenzen et al. 2012). 
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However other studies have reported a declined concentration of miRs in more severe CKD 
patients and following hemodialysis, independent of miR removal by the kidneys or dialysis 
(Neal, Michael et al. 2011; Emilian, Goretti et al. 2012), probably due to enzymatic 
degradation. MicroRNAs are suggested as a good indicator for progression of peritoneal 
fibrosis in patients undergoing peritoneal dialysis (Ge, Xiao et al. 2012), and even as 
biomarker for cardiovascular changes in hemodialysis patients (Wen, Song et al. 2014). Yet, 
there is a great need for studies in CKD patients to clarify the profile of miRs and their 
potential as biomarkers in these patients. 
1.7 IMPACT OF MEDICATIONS IN CKD 
An important factor, which can impact the analysis and interpretation of experimental data, is 
the patient selection. Most CKD patients take medications to manage complications such as 
high blood pressure, anemia, low levels of Vitamin D or high levels of PTH, and so forth. 
Some of these medications have been proposed to have an impact on the immune system, 
both negatively and positively. The later may be a treatment advantage to not only be applied 
for correction of the targeted abnormalities, but also to improve the immunity status in CKD 
patients. 
1.7.1 Angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor 
blocker (ARB) 
These medications are the first choice for treatment of high blood pressure in CKD patients, 
particularly in patients with proteinuria (Kunz, Friedrich et al. 2008). They have been 
proposed to better preserve renal function in patients with CKD (Wright, Bakris et al. 2002; 
Hou, Zhang et al. 2006). Moreover, further studies have revealed a beneficial effect of these 
medications to diminish inflammation (Fliser, Buchholz et al. 2004), to augment anti-
inflammatory T cells, and to modulate inflammatory T cells (Platten, Youssef et al. 2009). 
1.7.2 Erythropoiesis-stimulating agent (ESA) 
CKD patients suffer from anemia and therefore ESAs are often prescribed in these patients. 
Studies have shown that ESAs, such as recombinant human erythropoietin, can decrease 
inflammation (Bryl, Mysliwska et al. 1998), enhance proliferation and antibody production of 
activated B cells (Kimata, Yoshida et al. 1991), and improve the activation and proliferation 
capacity of CD4+ T cells (Lisowska, Debska-Slizien et al. 2010).  
1.7.3 Vitamin D 
CKD patients show a disturbance in bone mineral metabolism, including hypocalcemia, 
hyperphosphatemia, high PTH, and reduced levels of active vitamin D. Therefore, many 
patients are treated with phosphate binders and vitamin D analogues. Studies indicate that 
vitamin D has broader advantages than merely regulation of calcium and phosphate 
homeostasis. Reduction of albuminuria and cardiovascular events in ESRD patients has been 
reported following treatment with vitamin D (Alborzi, Patel et al. 2008; Lishmanov, 
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Dorairajan et al. 2013). Moreover, a positive impact of vitamin D supplementation on 
endothelial function has been suggested (Dreyer, Tucker et al. 2014; Zoccali, Curatola et al. 
2014; Lundwall, Jorneskog et al. 2015). 
Currently, we know that the active form of vitamin D is not only generated in the kidneys but 
also in many other cells including immune cells (Aranow 2011), which in turn interacts with 
the vitamin D receptor (VDR) and regulates their function. The VDR is a nuclear receptor, 
which affects the expression of a range of genes following activation (Hossein-nezhad, Spira 
et al. 2013). It can induce both inflammatory responses such as antimicrobial peptide 
production and bacterial killing, and anti-inflammatory responses by suppression of pro-
inflammatory cytokines, induction of anti-inflammatory cytokines, and Th2 and regulatory T 
cell differentiation (Vojinovic 2014). 
There are reports suggesting an association between vitamin D levels and inflammation and 
the role of vitamin D treatment in complications such as cardiovascular diseases (Chitalia, 
Ismail et al. 2014; Dreyer, Tucker et al. 2014; Yin and Agrawal 2014). Yet many questions 
remain unanswered concerning the role of vitamin D in controlling inflammation in CKD. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis is to increase the understanding of how the immune system 
operates in CKD patients and to address key issues in terms of immune insufficiency and 
inflammation in CKD patients. 
This thesis comprises four studies and their respective aims are: 
Study I. To investigate whether blood-membrane interaction has any impact on the human 
peripheral basophils and neutrophils in hemodialysis patients. 
Study II. To study the lymphocyte proliferation response and immune modulator production, 
following in vitro stimulation of cells from pre-dialysis and hemodialysis patients. 
Study III. To investigate the profile of CD4+ T cell subsets and cytokine production, 
following in vitro stimulation in hemodialysis patients.  
Study IV. To assess the effect of vitamin D receptor activation on the pro-inflammatory 
profile and up-stream gene expression regulators, micro RNAs, in moderate CKD.  
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3 MATERIAL AND METHODS 
This section comprises a description of the study participants (patients and healthy 
individuals), and the methodology used in the studies of this thesis. A more detailed 
description can be obtained within the ‘Material and Methods’ section of each paper (I-IV). 
3.1 STUDY POPULATION 
3.1.1 Patients 
Patients in studies I, II, and III were recruited from the Department of Nephrology at 
Karolinska University Hospital Solna, Stockholm, Sweden. Written informed consent was 
obtained from all participants and the local Ethics Committee in Stockholm, Sweden, 
approved all the studies. Patients in study IV were recruited from the Department of 
Nephrology at Danderyd University Hospital, Stockholm, Sweden. All patients provided 
written informed consent. The regional Ethics Committee in Stockholm, Sweden, approved 
the study protocol and the clinical trial was registered on clinicaltrials.gov (SOLID study; 
NCT01204528).  
None of the patients had been diagnosed with cancer, ongoing infection, chronic 
inflammatory and rheumatologic diseases, or received treatment with immunosuppressive 
drugs. 
3.1.1.1 Study I 
Patients (n=10) with an eGFR <20 mL/min/1.73 m
2 
(stage 5D) with a residual GFR from 6-
11 mL/min/1.73 m
2
 were recruited. Patients were undergoing hemodialysis with polysulfone 
high-flux dialyzers (effective surface area of 2.3 m
2
, K0A urea: 1421 mL/min, ultrafiltration 
coefficient: 76 mL/h/mm Hg), three times per week for four to four and a half hours per 
dialysis before the study. An arteriovenous fistula or a central dialysis catheter was used for 
dialysis.  
3.1.1.2 Study II 
Patients (n=14) with an eGFR <20 mL/min/1.73 m
2
 (predialysis, CKD stage 4 and 5), and 
patients (n=14) with eGFR <20 mL/min/1.73 m
2
 undergoing hemodialysis were recruited. 
Hemodialysis was performed three times per week for four to four and a half hours per 
dialysis with polysulfone high-flux dialyzers. Residual GFR ranged from 4-12 mL/min/1.73 
m
2
 (median 8.5). Dialysis was done through an arteriovenous fistula, graft or a central 
dialysis catheter (n=4). 
3.1.1.3 Study III 
Patients (n=10) with CKD stage 5D were recruited. Patients were undergoing maintenance 
hemodialysis for four hours/session, three times per week, using polysulfone high-flux 
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dialyzers. The residual GFR ranged from 4-12 mL/min/1.73 m
2
 (median 8.5). Dialysis was 
done via an arteriovenous fistula, graft or a central dialysis catheter.  
3.1.1.4 Study IV 
This was a sub-study of a clinical trial, the SOLID-trial. Patients (n=36) with eGFR of 15-59 
mL/min/1.73 m
2 
(CKD stage 3 and 4), a calcium level below 2.6 mmol/L, and a plasma PTH 
level of 3.7-53 pmol/mL were recruited in three groups: placebo (n=12), 1 µg paricalcitol 
(n=12), or 2 µg paricalcitol (n=12) daily, in a randomized, double-blinded manner. Further 
patient characteristics are shown in Table 1. 
 
 Male 
n (%) 
Age (y), 
range (median) 
CVD 
(n) 
ACE-I/ARB 
(n) 
ESA 
(n) 
Study I (n=10) 5 (50) 37–76 (62.5) Heart disease (4) 
Hypertension (9) 
5 9 
Study II      
   Predialysis (n=14) 
 
   
   Hemodialysis (n=14) 
 
9 (64) 
 
 
7 (50) 
 
33-65 (51) 
 
 
36-66 (53.5) 
 
Heart disease (1) 
Hypertension (14) 
 
Heart disease (3) 
Hypertension (7) 
 
         13 
 
           
          4 
 
      6 
 
      
     12 
Study III (n=10) 5 (50) 62-83 (71) Heart disease (5) 
Hypertension (5) 
3 9 
Study IV  
   Placebo (n=12) 
 
   1 μg paricalcitol (n=12) 
    
   2 μg paricalcitol (n=12) 
 
9(75%) 
 
11(92%) 
 
8 (67%) 
mean (SD) 
70.8 (10.0) 
 
66.1 (7.9) 
    
    59.1 (11.6) 
 
Heart disease (5) 
 Hypertension (3) 
  
Heart disease (3) 
Hypertension (4) 
 
Heart disease (1) 
 Hypertension (4) 
 
11 
 
9 
 
  9 
 
ND 
 
ND 
 
ND 
 
Table 1. Demographic characteristics of participants at baseline in study I-IV, CVD: Cardiovascular 
disease, ACE-I: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, ESA: 
erythropoiesis-stimulating agent, SD: standard deviation, ND: not determined. 
 
3.1.2 Healthy controls 
In study I, II and III, the healthy controls were recruited among healthy blood donors and 
were age and sex-matched (±5-7 years) with the patients. 
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3.2 STUDY METHODS 
3.2.1 Study I 
To perform the study, the dialyzer was shifted from high-flux to a low-flux polysulfone 
capillary dialyzer (effective surface area of 1.8 m
2
, K0A urea: 976 mL/min, ultrafiltration 
coefficient: 14 mL/h/mm Hg), in one session of treatment. Blood samples were collected 
before and after the dialysis procedure in each session (one occasion with a high-flux and one 
occasion with a low-flux dialyzer). 
3.2.1.1 Basophil activation  
Detection of surface expression of CD203c and CD63 on basophils was done by flow 
cytometry (Navios, Beckman Coulter), following treatment of whole blood with stimulators 
fMLP (Sigma Aldrich), and anti-FcεRI antibody (Bühlmann Laboratories). 
3.2.1.2 Counting of basophils 
Absolute number of basophils was determined using the ImmunoPrep reagent system 
(Beckman Coulter), cell-counting beads (Flow-Count Fluorospheres, Beckman Coulter), and 
flow cytometry (Navios). 
3.2.1.3 Neutrophil activation  
Detection of surface expression of CD11b and active CD11b on neutrophils was done by 
flow cytometry (Navios), following treatment of whole blood with IL-8 (CXCL8) (Research 
& Diagnostics Systems). 
3.2.1.4 Expression of CD88 (C5aR) on neutrophils 
Whole blood was incubated with anti-CD88 antibody (Becton Dickinson), and expression of 
CD88 was detected by flow cytometry (Navios). 
3.2.2 Study II 
3.2.2.1 Cell culturing with mitogens 
Whole blood was diluted in RPMI 1640 medium (Gibco) containing 2 mM L-glutamine 
(Gibco), 10 000 IU/mL Penicillin (Gibco) and 10 000 µg/mL Streptomycin (Gibco). 1 µg/mL 
of Pokeweed mitogen (PWM, Sigma-Aldrich), 1 µg/mL of Concanavalin A (Con A, Sigma-
Aldrich), 100 ng/mL of Staphylococcus enterotoxin A (SEA, Sigma-Aldrich), and Influenza 
A vaccine (IAV, Fluarix, GlaxoSmithKline AB) diluted 1:100, were added to blood-medium 
suspensions, and incubated at 37°C, 5 % CO2 for six days. 
3.2.2.2 Cell counting 
Cell count was performed using cell-counting beads (Flow-Count Fluorospheres), and flow 
cytometry (Navios). 
 22 
3.2.2.3 Flow cytometric Assay of Specific Cell-mediated Immune response in Activated 
whole blood (FASCIA) 
This method was applied for the detection of T lymphocyte proliferation and lymphoblast 
formation. Following staining with anti-CD3, -CD4, -CD8 and -CD45 (CYTO-STAT, tetra 
CHROME, Beckman Coulter), cells were analyzed by flow cytometry (Navios) (Fig. 4). 
 
 
Figure 4. Flow cytometric analysis of cell-mediated immune response in the activated whole blood. 
The CD45+ resting (blue color) and activated leukocytes (red color) from medium, and 
staphylococcus enterotoxin A (SEA)-stimulated cultures were gated according to their size and 
granularity on forward and side scatter plot. The CD3+CD4+ cells and CD3+CD8+ cells were then 
detected within the resting and lymphoblast population accordingly.  
 
3.2.2.4 Characterization of pro-inflammatory molecules  
Milliplex 26-plex (Millipore Corp.) was applied for measuring a broad range of cytokines and 
chemokines: eotaxin, granulocyte macrophage colony-stimulating factor (GM-CSF), 
granulocyte colony-stimulating factor (G-CSF), IFN-α2, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, interferon 
gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage 
inflammatory protein (MIP)-1α, MIP-1β, TNF-α and TNF-β (Lymphotoxin α) in plasma and 
culture supernatants. 
3.2.3 Study III 
3.2.3.1 Isolation of CD4+ cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density-
gradient centrifugation (Ficoll-Paque PLUS; GE Healthcare) and CD4+ cells were isolated by 
positive selection using a magnetic cell-sorting system (MACS, Miltenyi) 
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3.2.3.2 Cell count and purity check 
Cell count was performed using cell-counting beads (Flow-Count Fluorospheres) and flow 
cytometry (Navios). CD3+CD4+ (Becton Dickinson) staining was applied to check the purity 
of isolated cells. 
3.2.3.3 Cell culturing with superantigen; Staphylococcus enterotoxin A 
AIM-V medium (Life technologies), with or without addition of SEA, was utilized to culture 
the cells in vitro. 
3.2.3.4 Profiling the CD4+ T cells 
Cells were stained with Live/Dead Fixable Near-IR Dead cell stain kit (ThermoFisher 
scientific Inc.), anti-CD4 antibody (Becton Dickinson) and anti-CD25 (Becton Dickinson). 
Intracellular analysis of transcription factors by flow cytometry (Navios) was carried out, 
following fixation and permeabilization of cells using FOXP3/Transcription Factor staining 
buffer set kit (eBioecience Inc.), and staining with either anti-T-bet (eBioecience Inc.) anti-
GATA3 (Becton Dickinson) or anti-FOXP3 (Becton Dickinson).  
3.2.3.5 Characterization of soluble immune modulators in supernatants  
ELISA was applied to determine the concentration of cytokines: IFN-γ, IL-4, and IL-10 in 
supernatants (R&D Systems, USA). 
3.2.4 Study IV 
The study started with two weeks of placebo, followed by 12 weeks of intervention with 
placebo, 1 µg paricalcitol, or 2 µg paricalcitol daily. Blood samples were drawn at baseline 
and after 12 weeks, after 12 hours fasting and 20 min rest.  
3.2.4.1 RNA isolation from plasma  
The miRCURYTM RNA isolation kit Biofluids, (EXIQON) was applied for purification of 
total RNA, containing RNAs smaller than 1000 nt (such as miRNAs) from the plasma.  
3.2.4.2 Reverse transcription polymerase chain reaction (RT-qPCR) for profiling of 
microRNA expression 
Exiqon miRCURY Ready-to-Use PCR Human panel I + II V1.M (Exiqon miRNA qPCR 
panel) was applied to identify the potentially affected plasma microRNAs. RNA spike-in for 
quality control of the RNA isolation and cDNA synthesis was applied. RNA isolation control 
(UniSp2, UniSp4, UniSp5), cDNA synthesis control (UniSp6), and DNA spike-in (UniSp3) 
were also included. 
 24 
3.2.4.3 Reverse transcription polymerase chain reaction (RT-qPCR) for validation of 
microRNA expression 
Universal cDNA synthesis kit II (miRCURY LNATM Universal RT microRNA PCR, 
EXIQON), was applied for reverse transcription to cDNA. ExiLENT SYBR Green master 
mix kit (miRCURY LNATM Universal RT microRNA PCR, EXIQON) was used for RT-
qPCR. PCR reaction was performed with MicroAmp™ optical 384-well reaction plates using 
an ABI 7900 (Life Technology). 
3.2.4.4 Characterization of soluble immune modulators in plasma  
A broad range of cytokines was measured by Milliplex 26-plex (Millipore Corp.) in plasma at 
the baseline, and following 12 weeks of treatment. 
3.3 STATISTICAL ANALYSIS 
Statistical analysis in studies I-IV was done in GraphPad Prism 5 (GraphPad Software), 
STATISTICA version 10 (Stat Soft, Inc.), and SPSS version 22 (IMB, 2011). One-way 
ANOVA and repeated measures ANOVA was applied for analysis of normally distributed 
data (study IV). Wilcoxon matched-pairs signed-rank test for two dependent measurements 
(study I, IV), and Mann-Whitney U test for two independent sample groups (study III, IV) 
were applied to analyze non-normally distributed values. Nonparametric Kruskal-Wallis test 
was carried out for comparison of three independent measurements (study I, II, IV). 
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4 RESULTS AND DISCUSSION 
4.1 ALTERATION IN BASOPHIL ACTIVATION: A POTENTIAL MARKER FOR 
ASSESSMENT OF BIOCOMPATIBILITY IN HEMODIALYSIS (STUDY I)  
 
Hemodialysis is required to remove excess electrolytes, fluid and uremic toxins in ESRD. 
However, interaction between peripheral blood and the surface of the dialyzer membrane 
may lead to alterations in the cells and plasma proteins (Rao, Guo et al. 2004; Banche, 
Allizond et al. 2006). This so-called bioincompatibility is dependent on the surface material 
and the permeability properties of the membrane. In this study, we aimed to investigate the 
impact of this interaction on the activation of human peripheral basophils and neutrophils in 
patients undergoing dialysis with high- and low-flux polysulfone dialyzers. 
After stimulation with fMLP and anti-FcεRI antibody, basophil CD63 expression was 
analyzed since its expression represents degranulation of basophils and subsequent histamine 
release. Samples were obtained before each session of dialysis with high-flux or low-flux 
dialyzers, and compared to those from healthy controls. The fMLP-activated basophils from 
patients expressed significantly higher levels of CD63 compared with those in healthy 
controls (p= 0.04) (Fig. 5, A). However, this was not the case following stimulation with anti-
FcεRI antibody.  
We observed a higher response of basophils to fMLP in hemodialysis patients compared to 
healthy individuals. It is not clear whether this increased responsiveness is a consequence of 
altered fMLP receptor (FPR or FPRL1) expression, or whether the intracellular pathways 
(MEK–ERK pathway) involved in degranulation are primed in basophils from CKD patients 
(Miura, Schroeder et al. 1999; de Paulis, Montuori et al. 2004). Therefore, it is noteworthy to 
further analyze the mechanistic alterations involved in fMLP activation of basophils. 
The surface expression of CD63 on basophils was significantly increased after dialysis with 
low-flux dialyzers compared with high-flux dialyzers in both fMLP (p = 0.01) and anti-FcεRI 
antibody-activated cells (p= 0.002) (Fig. 5, B). Comparing predialysis and postdialysis 
samples, significantly higher CD63 expression was observed on anti-FcεRI antibody-
activated basophils, following hemodialysis with low-flux membranes (p= 0.002) (Fig. 5, B). 
Moreover, we found a similar absolute number of basophils, following hemodialysis with 
high-flux and low-flux dialyzers compared to that in healthy controls. This indicates that the 
differential basophil response was due to functional changes, and not the entrapment of low-
responding cells in the dialyzer. 
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Figure 5. Basophil activation response (CD63 expression) to fMLP and anti-FcεRI antibody 
comparing patients (before dialysis) with healthy controls (A), CD63 expression in activated 
basophils following dialysis with low-flux (LFD) and high-flux dialyzers (HFD)(B), and total CD11b 
expression on neutrophils after stimulation with IL-8 (C). 
 
The differences in FcεRI-mediated activation of basophils following passage through the 
low-flux dialyzer is of interest since anaphylactic reactions have been reported in patients 
undergoing hemodialysis. This strong response may arise from the cross-linking of Fcε 
receptors on the basophils and release of mediators such as histamine and Heparin (Ebo, 
Bosmans et al. 2006). It has also been shown that different membrane surfaces can lead to 
activation of Hageman factor and bradykinin which in turn may activate basophils in an IgE-
A. 
B. 
C. 
.. 
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independent manner and cause anaphylactic reactions during hemodialysis (Ebo, Bosmans et 
al. 2006). In this study, we suggest that the different pore size and ultrafiltration coefficient of 
the dialyzer membrane may have an impact on priming of the basophils and their activation. 
This supports the notion that high-flux dialyzers may be superior to low-flux dialyzers in this 
respect (Eknoyan, Beck et al. 2002; Cheung, Levin et al. 2003; Locatelli, Martin-Malo et al. 
2009). 
We analyzed the expression of CD11b on neutrophils since as a subunit of integrin molecule 
MAC-1 it is involved in neutrophil adhesion to endothelial cells, and transmigration to the 
site of inflammation. It has been shown that neutrophil CD11b expression increases during 
the hemodialysis procedure but falls down to the starting values using both low- and high-
flux membranes. However, the transmigration properties of neutrophils change following 
dialysis by low-flux membranes, despite the intact CD11b (Moshfegh, Jacobson et al. 2002). 
Additionally, in this study we analyzed the surface expression of the CD11b active epitope on 
neutrophils, since it interacts with RGD in ECM and promotes transmigration. IL-8 was 
applied since it is a potent chemotactic factor for neutrophils and induces the expression of 
CD11b. No significant differences were observed in terms of CD11b expression (MFI) on 
neutrophils either before stimulation (baseline), or after stimulation with IL-8 (Fig. 5, C), 
comparing dialysis patients with healthy controls and comparing high-flux dialyzer with low-
flux dialyzer, which was in line with the previous findings. Similar findings were observed 
with regard to the expression of active CD11b (percentage).  
Moreover, we analyzed the expression of C5aR (CD88) on neutrophils. It has been suggested 
that Anaphylatoxin C5a is induced by hemodialysis (Erlenkotter, Endres et al. 2008). It is a 
strong chemotactic and activation factor for neutrophils, leading to higher expression of 
adhesion molecules and expiratory burst (Mollnes, Brekke et al. 2002; Kourtzelis, 
Markiewski et al. 2010). C5a exerts its action through C5aR. C5a- C5aR interaction leads to 
cleavage of the receptor from the surface of the cells (van den Berg, Tambourgi et al. 2014), 
which indirectly indicates cell exposure to the anaphylatoxin. In our study, no significant 
differences were observed in terms of CD88 expression on neutrophils either before or after 
hemodialysis.  
In summary, we found no difference in CD11b expression and its active epitope on 
neutrophils following exposure to different dialysis modalities while basophils presented a 
significant difference in their functionality following low-flux hemodialysis. This may 
suggest a role for the basophils as a more sensitive marker for biocompatibility.  
4.2 DECLINED RESPONSE OF LEUKOCUTES TO IN VITRO STIMULATION IN 
CKD AND HEMODIALYSIS PATIENTS (STUDY II) 
ESRD is accompanied by a high inflammatory state and an immunodeficiency, and both the 
innate and adaptive immune sectors are affected (Kato, Chmielewski et al. 2008). 
Lymphocytes are altered in CKD, but there are contrasting findings on the net number of 
circulatory lymphocytes, the lymphoproliferative response to stimulators and cytokine 
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production (Ankersmit, Deicher et al. 2001; Lisowska, Debska-Slizien et al. 2012). In this 
study we applied the FASCIA technique to measure the proliferative response to selected 
stimulators in cells (Gaines, Andersson et al. 1996) from patients with CKD and 
hemodialysis patients, compared to healthy donors. This technique allows us to avoid extra 
manipulation and pre-activation of cells ex vivo by using conventional isolation protocols 
(Mookerjee 1976). Moreover, we applied a multi-array method to analyze a broad range of 
cytokines in peripheral blood and following stimulation with the mitogens.  
There were no significant differences between the three groups with regard to total leukocyte-
and platelet counts, and C-reactive protein (CRP). Following antigen-independent stimulation 
with SEA, a significant decline (p= 0.041) was observed in the absolute number of 
lymphoblasts in hemodialysis patients compared with healthy controls, but this was not the 
case following stimulation with other mitogens: ConA, IAV and PWM (Table 2, A). No 
significant differences were observed between the three groups in terms of the absolute 
numbers and percentage of the CD4+ (Table 2, B) and CD8+ cells in the activated 
population.  
 
 
Category SEA ConA IAV PWM 
Healthy subjects 27015 (21649-41925) 2086 (1264-3437) 3803 (1900-5824) 13286 (6929-18522) 
Pre-dialysis 19909 (7080-36776) 2503 (1763- 3568) 2180 (1212-4203) 16124 (7219-21602) 
Hemodialysis 15593 (9989-20346) 3846 (1417-6092) 2226 (1146-3957) 8393 (5341-10145) 
Significance p= 0.041 ns ns ns 
 
 
 
 
Category SEA ConA IAV PWM 
Healthy subjects 18311 (14880- 30002) 1423 (981-2805) 2033 (976-3201) 5301 (3274-10163) 
 69 (5-85)% 73 (4-86)% 68 (2-89)% 48 (9-75)% 
Pre-dialysis 13819 (6620-29523) 2108 (1516-2547) 1815 (769-2858) 7030 (3347-14297) 
 73 (40-83)% 83 (43-89)% 78 (10-96)% 55 (42-76)% 
Hemodialysis 10035 (7176-15777) 2583 (969-4510) 1411 (905-3214) 4467 (2118-5987) 
 70(61-89)% 68(46-93)% 78(27-96)% 59(10-84)% 
Significance ns ns ns ns 
 
Table 2. Absolute number of lymphoblasts (cells/µl)(A), and absolute number and percentage of 
CD4+ cells (cells/µl) in the lymphoblast population (cells/µl)(B), following in vitro stimulation. 
Values are given as median and interquartile range (25-75%). ns: non-significant.  
A. 
B. 
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There are reports showing a similar proliferation capacity of lymphocytes in hemodialysis 
patients and healthy controls (van Riemsdijk, Baan et al. 2001; van Riemsdijk, Baan et al. 
2003), which is in line with our findings, while other studies have shown a reduced 
proliferative response and a decline in the proportion of T cells in hemodialysis patients 
(Stachowski, Pollok et al. 1993; Lisowska, Debska-Slizien et al. 2012). The differences might 
be explained by experimental set-ups (the applied mitogens, isolation techniques etc.), and a 
variety in patient selection. In our study, we tried to eliminate some of the confounding 
factors by using whole blood, applying mitogens with different mechanisms, and age/sex-
matching the patients with healthy controls. 
After calculation of the ratio of cytokine concentration in each supernatant to medium, we 
found that IL-2, IL-10 and IL-15 were significantly lower in supernatant from SEA-
stimulated cells in hemodialysis patients compared with healthy controls (Fig. 6). Culture 
with IAV showed a significantly lower level of IL-5 in hemodialysis patients and a 
significantly lower level of IL-15 in pre-dialysis patients, compared to healthy subjects. The 
IL-2 level was also significantly lower in the supernatant from PWM-cultured cells in 
hemodialysis patients compared to pre-dialysis patients 
 
Figure 6. Cytokines with significantly different levels, released in the supernatants by cultured cells, 
following stimulation with SEA.  
 
Cytokines such as IL-2 and IL-15 are important for expansion of activated T lymphocytes 
(Ma, Koka et al. 2006), as well as proliferation and differentiation of B-lymphocytes 
(Armitage, Macduff et al. 1995). Therefore, decreased levels of IL-2, IL-10 and IL-15 in the 
SEA-stimulated supernatant are noteworthy. The lower production of these cytokines may 
lead to alterations in cellular immunity and a higher vulnerability to infections, and 
aberrations in the proliferation and antibody production of B-lymphocytes, followed by a 
lower response to vaccination in CKD patients. One limitation of our study was that the 
source of the cytokines could not be determined. 
Analysis of immune modulators in the plasma revealed significant differences in the levels of 
eotaxin, IFN-α2, IL-1α, IL-8, IL-10, IL-12 (p40), IL-15, IP-10, MCP-1 and TNF-α, 
comparing the three groups. This was a verification of the high inflammatory state in CKD 
patients, which has been previously mentioned (Rysz, Banach et al. 2006), and an important 
contributor to the risk of cardiovascular disease in these patients.  
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Interestingly, we observed a high level of eotaxin in CKD patients. Eotaxin is a chemotactic 
factor for basophils, and potentiates the expression and release of IL-4 by them 
(Devouassoux, Metcalfe et al. 1999). In our first study, we observed differences in the 
activation of circulatory basophils from CKD patients. Given the higher levels of eotaxin in 
the CKD patients in this study, we presume basophils play a role in the course of CKD. 
4.3 IMBALANCE IN T CELL PROFILE AND PRODUCTION OF SIGNATURE 
CYTOKINES, FOLLOWING ANTIGEN-INDEPENDENT ACTIVATION, IN 
HEMODIALYSIS PATIENTS (STUDY III) 
In study II, we reported that stimulation of T lymphocytes in whole blood from hemodialysis 
patients led to a lower level of selected cytokines such as IL-2 and IL-10. IL-2, and to some 
extent IL-10 are mainly produced by T lymphocytes, but since we applied whole blood, the 
interaction of different immune cells, and the source of pro-inflammatory molecules were not 
assessable. To gain more knowledge as to whether this picture originated from an abnormal 
antigen presentation, co-stimulation and the inflammatory milieu (dysregulation of T cells) 
and/or dysfunction of T cells per se, we analyzed the profile of T cells through signature 
transcription factors and production of cytokines. Following in vitro SEA-stimulation of 
isolated CD4+ cells, no significant differences in the fraction of live cells as well as 
CD4+CD25+ T cells were observed when comparing patients to healthy individuals. CD4+ 
CD25+ FOXP3+ T cell fraction values were significantly lower (p= 0.01) in patients 
compared to in healthy subjects. The fraction of CD4+GATA3+ (Th2) cells was also 
significantly lower (p= 0.02) in patients. However, CD4+T-bet+ T cell (Th1) fractions were 
similar, comparing the groups (Fig. 7, A).  
 
                                                                     
                      
Figure 7. Fraction of CD4+T-bet+ (Th1), CD4+GATA3+ (Th2), and CD4+CD25+Foxp3+ (Treg) 
cells, following stimulation with SEA (A), level of cytokines in the supernatants (B). 
A. 
B. 
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After normalization of cytokine levels in stimulated cultures against the levels in the medium 
controls, a significantly lower level of IL-4 (p= 0.02), and a significantly higher level of IFN-
γ (p= 0.005) were observed in CKD patients, while IL-10 levels were similar between the 
groups (Fig. 7, B). 
There are discrepancies in terms of the regulation and functionality of T lymphocytes in CKD 
patients. Some arguments emphasize the role of APCs, co-stimulation capacity and the 
inflammatory milieu, as the mainstay of T-cell functional aberrations (Girndt, Kohler et al. 
1993; Kelly 1994), while others stress changes in the profile and function of T-cells (Sester, 
Sester et al. 2000; Nitta, Akiba et al. 2002; Meier, Meier et al. 2008; Lisowska, Debska-
Slizien et al. 2012; Ma, Zhang et al. 2015). Concerning the T cell profile, there are also 
debates about whether a Th1-skewed profile is dominant in hemodialysis patients (Sester, 
Sester et al. 2000; Nitta, Akiba et al. 2002; Costa, Lima et al. 2008), or an imbalance in Th2, 
Th17, or Treg profile is present (Libetta, Rampino et al. 2001; Hendrikx, van Gurp et al. 
2009; Zhang, Hua et al. 2010). 
Since analysis of the T cell profile in patients with CKD have mostly been based on 
production of signature cytokines, in this study we analyzed the signature transcription 
factors as a higher checkpoint for profiling, combined with released cytokines. Higher levels 
of IFN-γ in the supernatants and a low proportion of GATA3+ T cells together with low IL-4 
levels in supernatants from hemodialysis patients suggest a Th1-skewed profile in these 
patients. No difference in the proportion of T-bet+ (Th1) cells may indicate a higher 
production and release of cytokines, rather than changes in the proportion of the IFN-γ 
producing cells. Previous studies have shown similar findings, despite analysis of PBMCs 
instead of isolated CD4+ T cells, and merely the release of cytokines (Daichou, Kurashige et 
al. 1999; Sester, Sester et al. 2000; Nitta, Akiba et al. 2002; Zhang, Hua et al. 2010; Baron, 
Belo et al. 2014). 
 IL-10 levels in hemodialysis patients were similar to healthy individuals, although we 
observed lower proportions of FOXP3+ (Treg) and GATA3+ (Th2) cells. This finding 
contrasts observations from our previous study, where we found a higher level of IL-10 in 
supernatants from healthy controls, following stimulation of whole blood.  Isolation of CD4+ 
T cells and omission of the majority of non-T IL-10-producing cells in this study may 
contribute to the relatively lower levels of IL-10 in healthy controls (similar levels to 
patients). Hence, complexity of the cellular network and cytokine production in different 
experimental settings must be considered. 
4.4 VITAMIN D RECEPTOR ACTIVATION REDUCES SELECTED CYTOKINES 
AND MICRORNAS INVOLVED IN ATHEROSCLEROSIS AND INFLAMMATION IN 
PATIENTS WITH MODERATE CKD (STUDY IV) 
Cardiovascular disease (CVD) is a major complication in CKD, partly due to endothelial 
dysfunction and chronic inflammation. Clinical data analysis in SOLID trial demonstrated 
that treatment with vitamin D receptor activator (VDRA)-paricalcitol maintains endothelial 
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function and capillary blood flow in CKD stage 3 and 4 patients (Lundwall, Jorneskog et al. 
2015). Moreover, vitamin D modulates the functionality of many cells including immune 
cells, and can alter the inflammatory milieu. Therefore in this study, we aimed to investigate 
whether this preserved endothelial function is a possible consequence of changes in pro-
inflammatory molecules, and altered up-stream gene expression regulators in the form of 
plasma miRs, following treatment with the vitamin D analogue.  
The level of cytokines and chemokines was determined in plasma before and after VDRA 
and placebo treatment. The pre-treatment measurements were well matched between all the 
groups. Comparing pre- and post-treatment values within each group, vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF) had significantly decreased 
levels following treatment; 1 µg and 2 µg paricalcitol, and so did IP-10 after treatment with 2 
µg paricalcitol. This was not the case when comparing pre- and post-measurements in the 
placebo group. PDGF and VEGF promote angiogenesis and progression of atherosclerotic 
plaques. IP-10 (CXCL10) attracts immune cells to the site of inflammation and maintains the 
inflammatory process. Decreased levels of these cytokines, following treatment with 
paricalcitol, may indicate that vitamin D dampens the inflammatory processes leading to 
endothelial dysfunction. 
Additionally, we collapsed the treated groups, similar to the clinical data analysis. We 
observed a wider range of cytokines being decreased following active treatment. 
An initial profiling was applied to identify potentially affected plasma microRNAs following 
treatment. Five patients, treated with 2 µg paricalcitol, were randomly selected and included 
in this analysis. The five top-ranked identified down regulated microRNAs after VDRA 
treatment (Table 3) were then subjected to validation in all patients. 
 
 
 
  
 
 
Table 3. The top-ranked changed plasma microRNAs, after treatment compared to before treatment, 
in patients treated with 2 µg paricalcitol. 
 
MiR 432-5p, miR 495-3p, and miR 576-5p, were significantly decreased, following treatment 
with 2 µg of paricalcitol (Fig. 8). A dose-response effect was also observed in the levels of 
miR 495. Having collapsed the treated groups, we observed a similar pattern. 
miR p-value Fold change  
hsa-miR-576-5p 0.04 -1.92 
hsa-miR-432-5p 0.05 -2.00 
hsa-miR-133a-3p 0.05 -2.13 
hsa-miR-495-3p 0.06 -2.07 
hsa-miR-874-3p 0.07 -1.94 
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Figure 8. Significantly changed miRs in plasma following treatment, comparing the three groups; 
placebo, 1 µg and 2 µg 
 
Circulating miRs have been suggested as new biomarkers, which can regulate the 
inflammatory processes and fibrosis in CKD, and cardiovascular diseases (Small, Frost et al. 
2010; Mi, Zhang et al. 2013). Reports have shown that low levels of DNA methylation and 
subsequent activation of a gene cluster including miR 432 are involved in atherosclerotic 
lesions (Aavik, Lumivuori et al. 2015). MiR 495 contributes to regulating the function and 
reactivity of platelets, and miR 576 is involved in the pro-inflammatory immune responses. 
Altogether, downregulation of these miRs by vitamin D treatment in our study might indicate 
a connection to the pro-inflammatory state seen in CKD patients, however further studies are 
warranted. 
One major limitation was the small study sample, and therefore we were not able to 
investigate the potential effects of varying doses of paricalcitol or gender on the miRNAs or 
cytokine levels. Initially our aim was to correlate the clinical data on endothelial function 
from the first part of SOLID trial with the cytokine and miR findings in this study, however, 
due to the limited sample size this was not possible. Even so, the findings in this randomized 
trial may suggest a role for vitamin D in dampening the inflammation, and supports the 
rationale for larger and longer studies to investigate the underlying mechanisms of the 
impacts of VDRA on endothelial function in CKD patients. 
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5 PRELIMINARY RESULTS 
5.1 PART I. 
Down regulation of genes related to selenium signaling pathway in in-vivo 
transmigrated neutrophils from patients with Chronic Kidney Disease 
The most common causes of morbidity in patients with Chronic Kidney Disease (CKD) 
emerge from the dysregulation of the immune system. Granulocytes are less functional in 
terms of transmigration to the inflammatory sites. We analyzed the gene expression of 
neutrophils from peripheral blood and in-vivo transmigrated neutrophils, collected by skin 
chamber technique (Fig. 9), in CKD patients as well as healthy controls. We found that 
transmigration induced a significant change in the gene expression and kidney failure had 
different impacts on the gene expression of neutrophils in peripheral blood and upon in vivo 
transmigration compared to healthy subjects. After Cluster analysis of the significant genes 
and subjecting them to signaling pathways, we found the selenium-signaling pathway as one 
of those which was significantly impaired in transmigrated neutrophils from CKD patients. 
This comprised down regulation of genes such as; Glutathione peroxidase-1 (GPx-1), 
Superoxide dismutase 2 (SOD2), Peroxiredoxin-1(PRDX1), and Selenoprotein W (SelW) 
gene. Selenoproteins play a major role in antioxidant defense. Thus our results may indicate 
that the CKD patients have a deficiency in these components, leading to the oxidative stress 
in neutrophils and their impairment. These findings, however, warrant further investigation 
and we are currently in the process of setting up an in-vitro system to analyze the effect of 
selenium compounds on different functions of neutrophils from CKD patients (Abstract, The 
Journal of Immunology May 1, 2015 vol.194 (1 Supplement) 132). 
 
                             
 
Figure 9. Formation of blisters; A) Vacuum and heating, B) Blister formation in 2-3 h, C) 
Aspiration of exudate and removal of roof after 14h, D) Challenge with autologous serum (Thylen, 
Lundahl et al. 2000). 
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5.2 PART II.  
Impact of selenium-containing enzymes on neutrophils 
We also aimed to analyze the effect of the selenium-containing enzyme on the expression 
of adhesion molecule CD11b and metabolic activation (respiratory burst) in healthy 
neutrophils, following activation. We treated the whole blood with an organoselenium 
compound, Ebselen, which mimics glutathione peroxidase activity. Following treatment 
with Ebselen, the cells were activated with either lipopolysaccharide (LPS) or fMLP. 
Neutrophil CD11b expression and intracellular H2O2 production (dichlorofluorescein) were 
analyzed by flow cytometry. We observed a significant decrease in neutrophil CD11b 
expression and metabolic activation following 3h treatment with Ebselen in a dose dependent 
manner. These findings confirm the fact that selenium-containing enzymes impact the 
expression of CD11b in neutrophils and dampen the oxidative burst simultaneously.   
5.3 FUTURE PLANS 
We will further investigate the levels of these antioxidant enzymes in neutrophils at the 
protein level, as well as selenium levels in the serum from patients and healthy individuals. 
This may support the hypothesis that treatment of CKD patients with selenium potentiates the 
antioxidant enzymes, resulting in a better cell response to oxidative stress, and therefore a 
better functionality of cells. 
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6 CONCLUSIONS  
 
I. Our data showed for the first time that blood-dialyzer interaction impacts the 
basophils responsiveness in patients on maintenance hemodialysis, and that anti-
FcεRI stimulation is affected when the cells pass through a dialyzer. Responsiveness 
of basophils differed when low- or high-flux polysulfone membranes were applied.  
An increased responsiveness to fMLP in patients on hemodialysis was observed, 
compared with healthy controls. Interestingly, no concomitant changes in neutrophil 
activation were noticed. Taken together, these data suggest that basophil activation 
may be a new and more sensitive marker for evaluating dialyzer biocompatibility 
properties. A more biocompatible dialysis procedure may result in improved patient 
outcomes in terms of morbidity and mortality. 
 
II. In this study, the T cell proliferation was similar following stimulation with different 
mitogens in vitro. However, there was a reduced capacity of immune modulator 
production. Since whole blood was applied to perform the experiments, it was not 
possible to distinguish the source of cytokines, yet the low level of cytokine 
production in vitro, together with the contrasting high levels of inflammatory 
cytokines in plasma, may suggest exhaustion or inability of immune cells to produce 
cytokines due to the uremic milieu, and/or a consequence of therapeutic intervention 
(hemodialysis).  
 
III. This was a follow-up on study II where we observed a declined level of selected 
cytokines, following stimulation of lymphocytes in whole blood from CKD patient. 
Our main finding in this study was that there is an imbalance in the T cell profile and 
production of signature cytokines following antigen-independent activation of 
isolated CD4+ cells from patients. This imbalance is characterized by a low 
proportion of FOXP3+ T cells and Th2 cells, a low level of IL-4, and a high IFN-γ 
production. By combining cytokine analysis and transcription factors, we also 
discussed the complexity of the cellular and cytokine network in different 
experimental set-ups. Taken together, these findings increase our undertstanding of 
the potential factors involved in an increased susceptiblity to cardiovascular diseases 
and infections, observed in CKD patients and hemodialysis patients. 
 
IV. In this clinical trial, we found that treatment with active vitamin D-paricalcitol, in 
moderate CKD, reduces selected pro-inflammatory cytokines and down regulates 
miRs involved in atherosclerosis, immune response and platelet function. This 
supports the hypothesis that diminishing inflammation in moderate CKD patients by 
activated vitamin D treatment may in turn affect and improve endothelial and vascular 
function. Future studies are warranted to investigate the long term effects of treatment 
with VRDA on the incidence of cardiovascular diseases in patients with CKD. 
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Altogether in this thesis, we addressed questions regarding inflammatory state and function of 
immune cells in patients with renal failure at earlier stages of the disease, as well as in ESRD.  
We reported that chronic renal failure and hemodialysis procedure contribute to inflammation 
and alteration in innate and adaptive immune cells. This is noteworthy since a high 
inflammatory state in CKD patients contributes to higher prevalence of cardiovascular 
diseases. Moreover, the alteration in functionality of immune cells and a consequent immune 
deficiency leads to recurrent infections and low response to vaccinations. These 
complications can further deteriorate the patient’s condition, contribute to the progression of 
the disease, and lead to high mortality in CKD patients.  
We also showed that treatment with vitamin D analogues diminishes the inflammatory 
cytokines and miRs, which may play a role in atherosclerosis and inflammatory processes. 
Small interventional studies propose positive effects of vitamin D treatment on endothelial 
function, which is an independent risk factor for cardiovascular diseases. However, the role 
of vitamin D treatment in controlling inflammation is still unclear. We hope that our findings 
provide informative insight into the potential role of vitamin D receptor activator in reducing 
the inflammation in CKD patients, and the possible effect on the end point disease-related 
consequences such as higher risk of cardiovascular disease. 
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